次世代糖尿病治療&薬物送達の世界市場2020-2030:機会分析・産業予測

◆英語タイトル:Next Generation Diabetes Therapy and Drug Delivery Market By Product (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas), By Demographic (Adult Population (>14years), Child Population (14years)), By Indication (Type 1 Diabetes, Type 2 Diabetes), By End User (Diagnostic/Clinics, ICUs, Home Healthcare): Global Opportunity Analysis and Industry Forecast, 2020-2030

Allied Market Researchが発行した調査報告書(ALD22AU203)◆商品コード:ALD22AU203
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2022年3月
◆ページ数:254
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,540 ⇒換算¥819,920見積依頼/購入/質問フォーム
5 UserUSD6,654 ⇒換算¥984,792見積依頼/購入/質問フォーム
Enterprise UserUSD10,280 ⇒換算¥1,521,440見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Allied Market Research社は、2020年に7,080.6百万ドルであった世界の次世代糖尿病治療&薬物送達市場が、2021年から2030年まで年平均14.28%成長し、2030年までに28,044.23百万ドルに達すると予測しています。当書では、次世代糖尿病治療&薬物送達の世界市場を対象に総合的に調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、製品別(吸入インスリン、経口インスリン、インスリンパッチ、CGMシステム、人工膵臓)分析、デモグラフィック別(成人(14歳以上)、小児(14歳以下))分析、疾患別(1型糖尿病、2型糖尿病)分析、エンドユーザー別(診断/クリニック、ICU、在宅医療)分析、地域別分析、企業状況、企業情報などの項目をまとめております。なお、当書に掲載されている企業情報には、Abbott laboratories、Dexcom, Inc、Eli Lilly and Company、Glysens Incorporated、Johnson & Johnson、MannKind Corporation、Medtronic plc、Novo Nordisk A/S、Sanofi S.A.、Senseonics Holdings, Inc.などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の次世代糖尿病治療&薬物送達市場規模:製品別(吸入インスリン、経口インスリン、インスリンパッチ、CGMシステム、人工膵臓)
・世界の次世代糖尿病治療&薬物送達市場規模:デモグラフィック別(成人(14歳以上)、小児(14歳以下))
・世界の次世代糖尿病治療&薬物送達市場規模:疾患別(1型糖尿病、2型糖尿病)
・世界の次世代糖尿病治療&薬物送達市場規模:エンドユーザー別(診断/クリニック、ICU、在宅医療)
・世界の次世代糖尿病治療&薬物送達市場規模:地域別
・企業状況
・企業情報

The global next generation diabetes therapy and drug delivery market was valued at $7,080.6 million in 2020 and is projected to reach $28,044.23 million by 2030, registering a CAGR of 14.28% from 2021 to 2030. The next generation diabetes therapy and the drug delivery devices are the advanced form of diabetic products that improve the quality of life of diabetic patients. These products help in the management of the blood glucose level of diabetic patient in minimally invasive manner. Oral and inhalable insulin introduce a different mode of insulin delivery in diabetic patients. It is a painless mode of introducing insulin than the injectable insulins, reducing the risk of skin irritation caused due to needles. In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. Advanced diabetic therapy in the form of insulin patches, continuous glucose monitoring systems (CGMS), and artificial pancreas helps to improve management of blood sugar level and reduces the risk of any diabetic-related complications.
The main factors that drive the growth of the next generation diabetes therapy and the drug delivery market include, the benefits of using these advanced devices over conventional products and rise in the healthcare expenditure.
In addition, rise in incidences of diabetes globally and increase in the disposable income among the diabetic patients, further supplement the global next generation diabetes therapy and drug delivery market growth.
Conversely lack of awareness, cost restrains in the developing regions, and less variability in products are expected to obstruct the growth of the market during forecast years. On the other hand, development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to offer profitable opportunities for the growth of the market during the forecast period.

The global next generation diabetes therapy and drug delivery market is segmented based on product, demographic, indication, end user, and region. On the basis of product, it is classified into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. On the basis of demographics, it is bifurcated into adult population (>14 years) and child population (≤14 years). By indication, it is divided into type 1 diabetes and type 2 diabetes. On the basis of end users, it is categorized into diagnostics/clinics, ICUs, and home healthcare. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key market players profiled in the report include Abbott Laboratories, Medtronic, Inc., Sanofi S.A., Novo Nordisk, MannKind Corporation, Eli Lilly and Company, Dexcom, Inc., Senseonics Holding, Inc., Glysens Incorporated, and Johnson & Johnson.

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the next generation diabetes therapy and drug delivery market analysis from 2020 to 2030 to identify the prevailing next generation diabetes therapy and drug delivery market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the next generation diabetes therapy and drug delivery market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global next generation diabetes therapy and drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product
● Inhalable Insulin
● Oral Insulin
● Insulin Patches
● CGM Systems
● Artificial Pancreas

By Demographic
● Adult Population (and14years)
● Child Population (14years)

By Indication
● Type 1 Diabetes
● Type 2 Diabetes

By End User
● Diagnostic/Clinics
● ICUs
● Home Healthcare

By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ U.K.
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ China
○ Japan
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA

● Key Market Players
○ Abbott laboratories
○ Dexcom, Inc
○ Eli Lilly and Company
○ Glysens Incorporated
○ Johnson & Johnson
○ MannKind Corporation
○ Medtronic plc
○ Novo Nordisk A/S
○ Sanofi S.A.
○ Senseonics Holdings, Inc.

❖ レポートの目次 ❖

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Inhalable Insulin
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oral Insulin
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Insulin Patches
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 CGM Systems
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Artificial Pancreas
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC
5.1 Overview
5.1.1 Market size and forecast
5.2 Adult Population (>14years)
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Child Population (14years)
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Type 1 Diabetes
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Type 2 Diabetes
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Diagnostic/Clinics
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 ICUs
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Home Healthcare
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
CHAPTER 8: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Product
8.2.3 North America Market size and forecast, by Demographic
8.2.4 North America Market size and forecast, by Indication
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Market size and forecast, by Product
8.2.6.1.2 Market size and forecast, by Demographic
8.2.6.1.3 Market size and forecast, by Indication
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Product
8.2.6.2.2 Market size and forecast, by Demographic
8.2.6.2.3 Market size and forecast, by Indication
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Product
8.2.6.3.2 Market size and forecast, by Demographic
8.2.6.3.3 Market size and forecast, by Indication
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Product
8.3.3 Europe Market size and forecast, by Demographic
8.3.4 Europe Market size and forecast, by Indication
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Product
8.3.6.1.2 Market size and forecast, by Demographic
8.3.6.1.3 Market size and forecast, by Indication
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Product
8.3.6.2.2 Market size and forecast, by Demographic
8.3.6.2.3 Market size and forecast, by Indication
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 U.K.
8.3.6.3.1 Market size and forecast, by Product
8.3.6.3.2 Market size and forecast, by Demographic
8.3.6.3.3 Market size and forecast, by Indication
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Product
8.3.6.4.2 Market size and forecast, by Demographic
8.3.6.4.3 Market size and forecast, by Indication
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Product
8.3.6.5.2 Market size and forecast, by Demographic
8.3.6.5.3 Market size and forecast, by Indication
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Product
8.3.6.6.2 Market size and forecast, by Demographic
8.3.6.6.3 Market size and forecast, by Indication
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Product
8.4.3 Asia-Pacific Market size and forecast, by Demographic
8.4.4 Asia-Pacific Market size and forecast, by Indication
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 China
8.4.6.1.1 Market size and forecast, by Product
8.4.6.1.2 Market size and forecast, by Demographic
8.4.6.1.3 Market size and forecast, by Indication
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 Japan
8.4.6.2.1 Market size and forecast, by Product
8.4.6.2.2 Market size and forecast, by Demographic
8.4.6.2.3 Market size and forecast, by Indication
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 India
8.4.6.3.1 Market size and forecast, by Product
8.4.6.3.2 Market size and forecast, by Demographic
8.4.6.3.3 Market size and forecast, by Indication
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 Australia
8.4.6.4.1 Market size and forecast, by Product
8.4.6.4.2 Market size and forecast, by Demographic
8.4.6.4.3 Market size and forecast, by Indication
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Product
8.4.6.5.2 Market size and forecast, by Demographic
8.4.6.5.3 Market size and forecast, by Indication
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Market size and forecast, by Product
8.4.6.6.2 Market size and forecast, by Demographic
8.4.6.6.3 Market size and forecast, by Indication
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Product
8.5.3 LAMEA Market size and forecast, by Demographic
8.5.4 LAMEA Market size and forecast, by Indication
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Product
8.5.6.1.2 Market size and forecast, by Demographic
8.5.6.1.3 Market size and forecast, by Indication
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Product
8.5.6.2.2 Market size and forecast, by Demographic
8.5.6.2.3 Market size and forecast, by Indication
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Product
8.5.6.3.2 Market size and forecast, by Demographic
8.5.6.3.3 Market size and forecast, by Indication
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Product
8.5.6.4.2 Market size and forecast, by Demographic
8.5.6.4.3 Market size and forecast, by Indication
8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Abbott laboratories
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Dexcom, Inc
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Eli Lilly and Company
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Glysens Incorporated
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Johnson & Johnson
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 MannKind Corporation
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Medtronic plc
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 Novo Nordisk A/S
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 Sanofi S.A.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 Senseonics Holdings, Inc.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INHALABLE INSULIN, BY REGION , 2020-2030,($MILLION)
TABLE 3. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INHALABLE INSULIN BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ORAL INSULIN, BY REGION , 2020-2030,($MILLION)
TABLE 5. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ORAL INSULIN BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INSULIN PATCHES, BY REGION , 2020-2030,($MILLION)
TABLE 7. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INSULIN PATCHES BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CGM SYSTEMS, BY REGION , 2020-2030,($MILLION)
TABLE 9. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CGM SYSTEMS BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ARTIFICIAL PANCREAS, BY REGION , 2020-2030,($MILLION)
TABLE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ARTIFICIAL PANCREAS BY COUNTRY, 2020-2030,($MILLION)
TABLE 12. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 13. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ADULT POPULATION (>14YEARS), BY REGION , 2020-2030,($MILLION)
TABLE 14. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ADULT POPULATION (>14YEARS) BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CHILD POPULATION (14YEARS), BY REGION , 2020-2030,($MILLION)
TABLE 16. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CHILD POPULATION (14YEARS) BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 18. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 1 DIABETES, BY REGION , 2020-2030,($MILLION)
TABLE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 1 DIABETES BY COUNTRY, 2020-2030,($MILLION)
TABLE 20. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 2 DIABETES, BY REGION , 2020-2030,($MILLION)
TABLE 21. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 2 DIABETES BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 23. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR DIAGNOSTIC/CLINICS, BY REGION , 2020-2030,($MILLION)
TABLE 24. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET DIAGNOSTIC/CLINICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 25. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ICUS, BY REGION , 2020-2030,($MILLION)
TABLE 26. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ICUS BY COUNTRY, 2020-2030,($MILLION)
TABLE 27. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR HOME HEALTHCARE, BY REGION , 2020-2030,($MILLION)
TABLE 28. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET HOME HEALTHCARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 30. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 31. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 32. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 33. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 34. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 35. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 36. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 37. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 38. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 39. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 40. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 41. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 42. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 43. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 44. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 45. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 46. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 47. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 48. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 49. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 50. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 51. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 52. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 53. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 54. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 55. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 56. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 57. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 58. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 59. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 60. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 61. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 62. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 63. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 64. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 65. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 66. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 67. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 68. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 69. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 70. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 71. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 72. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 73. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 74. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 75. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 76. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 77. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 78. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 79. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 80. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 81. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 82. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 83. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 84. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 85. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 86. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 87. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 88. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 89. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 90. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 91. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 92. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 93. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 94. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 95. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 96. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 97. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 98. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 99. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 100. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 101. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 102. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 103. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 104. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 105. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 106. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 107. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 108. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 109. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 110. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 111. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 112. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 113. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 114. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 115. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 116. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 117. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 118. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 119. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 120. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 121. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 122. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 123. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 124. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 125. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 126.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 127.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 128.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 129.ABBOTT LABORATORIES: NET SALES,
TABLE 130.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 131.DEXCOM, INC: COMPANY SNAPSHOT
TABLE 132.DEXCOM, INC: OPERATING SEGMENTS
TABLE 133.DEXCOM, INC: PRODUCT PORTFOLIO
TABLE 134.DEXCOM, INC: NET SALES,
TABLE 135.DEXCOM, INC: KEY STRATERGIES
TABLE 136.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 137.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 138.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 139.ELI LILLY AND COMPANY: NET SALES,
TABLE 140.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 141.GLYSENS INCORPORATED: COMPANY SNAPSHOT
TABLE 142.GLYSENS INCORPORATED: OPERATING SEGMENTS
TABLE 143.GLYSENS INCORPORATED: PRODUCT PORTFOLIO
TABLE 144.GLYSENS INCORPORATED: NET SALES,
TABLE 145.GLYSENS INCORPORATED: KEY STRATERGIES
TABLE 146.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 147.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 148.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 149.JOHNSON & JOHNSON: NET SALES,
TABLE 150.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 151.MANNKIND CORPORATION: COMPANY SNAPSHOT
TABLE 152.MANNKIND CORPORATION: OPERATING SEGMENTS
TABLE 153.MANNKIND CORPORATION: PRODUCT PORTFOLIO
TABLE 154.MANNKIND CORPORATION: NET SALES,
TABLE 155.MANNKIND CORPORATION: KEY STRATERGIES
TABLE 156.MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 157.MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 158.MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 159.MEDTRONIC PLC: NET SALES,
TABLE 160.MEDTRONIC PLC: KEY STRATERGIES
TABLE 161.NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 162.NOVO NORDISK A/S: OPERATING SEGMENTS
TABLE 163.NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 164.NOVO NORDISK A/S: NET SALES,
TABLE 165.NOVO NORDISK A/S: KEY STRATERGIES
TABLE 166.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 167.SANOFI S.A.: OPERATING SEGMENTS
TABLE 168.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 169.SANOFI S.A.: NET SALES,
TABLE 170.SANOFI S.A.: KEY STRATERGIES
TABLE 171.SENSEONICS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 172.SENSEONICS HOLDINGS, INC.: OPERATING SEGMENTS
TABLE 173.SENSEONICS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 174.SENSEONICS HOLDINGS, INC.: NET SALES,
TABLE 175.SENSEONICS HOLDINGS, INC.: KEY STRATERGIES

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 次世代糖尿病治療&薬物送達の世界市場2020-2030:機会分析・産業予測(Next Generation Diabetes Therapy and Drug Delivery Market By Product (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas), By Demographic (Adult Population (>14years), Child Population (14years)), By Indication (Type 1 Diabetes, Type 2 Diabetes), By End User (Diagnostic/Clinics, ICUs, Home Healthcare): Global Opportunity Analysis and Industry Forecast, 2020-2030)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆